OakChart

Palisade Bio Inc

PALIHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.17+0.04 (3.54%)
2026-11-12 01:02 CET
Market cap
196.93 USD m
Revenue, TTM
0.50 USD m
Net income, TTM
-43.70 USD m
Free cash flow, TTM
-26.40 USD m
EPS diluted, TTM
-0.22
P/E
-
Compare

Price

PALI against its 20, 50 and 200-day averages
2050200beatmiss
1.502.0011.6M23.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PALIclose 1.1720-day 1.2650-day 1.52200-day 1.831.1752w low

59.0% under the 52-week high of 2.86 on 22 Apr 2026. 52-week low 1.08 on 2 Nov 2026. Last 15 sessions, 30.6% high to low

Volume 0.96× normal · the line is the 50-bar volume average

Profile

PALI
52-week range, 5% of the way up
1.082.86

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies for inflammatory bowel diseases. Its programs include PALI-2108 and LB1148. The company was founded on September 6, 2011 and is headquartered in Denver, CO.

IndexRUT
Employees14
IPODec 20, 2006
Beta1.61
ATR, 14d0.10
Rel volume0.96
Short float18.22%
Insider own7.77%
Inst own100.30%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap203.90M
Enterprise Value90.29M
Income-43.70M
Sales0.50M
Book/sh0.64
Cash/sh0.65
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPODec 20, 2006

Ratios

P/E-
Forward P/E-
PEG-
P/S407.80
P/B1.82
P/C1.79
P/FCF-
EV/EBITDA-
EV/Sales180.58
Quick Ratio20.15
Current Ratio20.15
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.22
EPS next Y-0.30
EPS next Q-0.07
EPS this Y21.67%
EPS next Y-29.79%
EPS next 5Y-5.13%
EPS past 3/5Y89.33% 88.75%
Sales past 3/5Y- -
EPS Y/Y TTM94.77%
Sales Y/Y TTM-
EPS Q/Q82.02%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.-14.75% -

Ownership

Insider Own7.77%
Insider Trans-0.39%
Inst Own100.30%
Inst Trans8.84%
ROA-69.63%
ROE-75.56%
ROIC-38.86%
Gross Margin-0.40%
Oper. Margin-9625.40%
Profit Margin-8739.20%
SMA20-6.96%
SMA50-22.79%
SMA200-35.91%
Trades-

Technical

Shs Outstand174.44M
Shs Float160.72M
Short Float18.22%
Short Ratio9.52
Short Interest29.29M
52W High2.86 -59.02%
52W Low1.08 8.33%
Volatility8.32% 8.64%
ATR (14)0.10
RSI (14)39.81
Beta1.61
Rel Volume0.96
Avg Volume3.08M
Volume2,965,009

Performance

Perf Week-6.40%
Perf Month-20.14%
Perf Quarter-45.58%
Perf Half Y-37.43%
Perf YTD-50.21%
Perf Year-35.71%
Perf 3Y-85.28%
Perf 5Y-99.94%
Perf 10Y-100.00%
Recom1.09
Target Price9.00
Prev Close1.13
Price1.17
Change %3.54%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Oct 09, 2026InitiatedRRaymond JamesOutperform$6+412.8%
Jul 23, 2026InitiatedOOppenheimerOutperform$8+583.8%
Apr 09, 2026InitiatedWWolfe ResearchOutperform$7+498.3%
Mar 26, 2026InitiatedHH.C. WainwrightBuy$7+498.3%
Feb 25, 2026InitiatedSStifelBuy$5+327.4%
Jan 09, 2026InitiatedRB. Riley SecuritiesBuy$7+498.3%
Dec 29, 2025InitiatedPPiper SandlerOverweight$25+2,036.8%

Peers

Mkt cap
TickerCompanyMkt cap
ABVXAbivax ADR8.01B
SYRESpyre Therapeutics Inc10.14B
IMUXImmunic Inc110.79M
ANABAnaptysBio Inc1.46B
PTGXProtagonist Therapeutics Inc8.80B
ARQTArcutis Biotherapeutics Inc3.59B
MCRBSeres Therapeutics Inc15.29M
ALMSAlumis Inc883.74M
ENTXEntera Bio Ltd560.73M
ABBVAbbvie Inc521.41B

Insider trading

latest 14 of 17
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Williams Donald AllenDirectorOct 02 '26Buy1.4610,00014,6001,590,294Oct 05 05:20 PM
Williams Donald AllenDirectorOct 01 '26Buy1.4210,00014,2001,580,294Oct 05 05:20 PM
Baltera Robert Jr.DirectorJul 09 '26Buy1.9625,00048,900461,904Jul 10 06:14 PM
Baltera Robert Jr.DirectorJul 08 '26Buy1.9920,00039,798436,904Jul 10 06:14 PM
Baltera Robert Jr.DirectorJul 07 '26Buy2.0330,00061,044416,904Jul 08 06:56 PM
Baltera Robert Jr.DirectorJul 06 '26Buy2.0520,00041,040386,904Jul 08 06:56 PM
Jones Mitchell LawrenceChief Medical OfficerJul 07 '26Sale2.0551,880106,53694,009Jul 08 06:52 PM
Finley John DavidCEO, CFOJul 07 '26Option Exercise0.7013393217,688Jul 08 06:49 PM
Finley John DavidCEO, CFOJul 07 '26Sale2.07146,798303,343217,555Jul 08 06:49 PM
Jones Mitchell LawrenceOfficerJul 07 '26Proposed Sale2.0453,000108,120Jul 07 05:18 PM
Finley John DavidOfficerJul 07 '26Proposed Sale2.07146,798303,343Jul 07 04:59 PM
Baltera Robert Jr.DirectorJul 01 '26Buy1.9820,00039,600356,904Jul 06 07:48 PM
Baltera Robert Jr.DirectorJul 02 '26Buy1.9810,00019,800366,904Jul 06 07:48 PM
Jones Mitchell LawrenceChief Medical OfficerFeb 12 '26Sale1.751,9893,48113,263Feb 13 08:10 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
SURISimplify Propel Opportunities ETFAUM: 74.30M
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs (GlobeNewswire) -5.04%
  • Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire)
  • Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 (GlobeNewswire) +6.72%
  • Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn's Disease at ACG 2026 (GlobeNewswire)
  • Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 (GlobeNewswire)
  • Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance (GlobeNewswire) -5.33%
  • Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD (GlobeNewswire)
  • Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire) +6.29%
  • Palisade Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development (GlobeNewswire)
  • Palisade Bio to Participate in the Leerink Partners Therapeutics Forum (GlobeNewswire)
  • PALI Stock Heads For Best Day In Seven Months Whats Driving Todays Rally? (Stocktwits) +17.99%
  • Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis (GlobeNewswire)
  • Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors (GlobeNewswire) +5.95%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.070-0.061-0.0700.170.0010
2026Q22026-08-10-0.050-0.052-0.0500.500.009
2026Q12026-05-12-0.050-0.043-0.0460.000.007
2025Q42026-03-25-0.036-0.036-0.0560.000.005
2025Q32025-11-17-0.380-0.295-0.3840.00-3
2025Q22025-08-19-0.580-0.594-0.5800.00-3
2025Q12025-05-09-0.468-0.700-0.4650.00-3
2024Q42025-03-14-1.175-1.987-2.7900.000.003
2024Q32024-11-12-2.320-3.353-2.3240.00-2
2024Q22024-08-13-3.320-2.930-3.3210.25-2
2024Q12024-05-14-4.590-3.750-4.5920.25-1
2023Q42024-03-27-3.600-5.191-4.807--2
2023Q32023-11-10-7.350-5.925-7.377--2
2023Q22023-08-11-7.950-6.825-7.930--2
2023Q12023-05-12-8.100-10.842-8.1340.250.002
2022Q42023-03-2397.050-36.525-20.4190.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-227,700-216,450-227,2610.020.01
2017FY-108,000--108,0000.26-
2021FY-2,543-2,940-2,5460.000.00
2022FY-247.95-321.45-247.89-0.00
2023FY-27.000-28.145-27.008-0.25
2024FY-10.190-11.663-10.1930.000.00
2025FY-0.300-0.544-0.3000.000.00
2026FY--0.235--0.44
2027FY--0.305--0.00
2028FY--0.349--0.00
2029FY--0.447--0.00
2030FY--0.280--374.14

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-114000.000.000.00
2026Q4S2026-11-103000.000.000.00
2026Q4S2026-08-133000.000.000.00
2026Q4S2026-08-112000.000.000.00
2026Q4S2026-05-312000.000.000.00
2026Q4S2026-05-133000.000.000.00
2026Q4S2026-04-203000.000.000.00
2026Q4S2026-04-172000.000.000.00
2026Q4S2026-03-253000.000.000.00
2026Q4S2026-01-073000.000.000.00
2026Q4S2025-12-262000.000.000.00
2026Q4R2026-11-11502-0.07-0.09-0.06
2026Q4R2026-11-10500-0.07-0.09-0.06
2026Q4R2026-10-25500-0.07-0.09-0.06

Estimate history

EPS, annual-108000-29241.9-17102.88-16742.16-2546.16-247.89-27.008-10.193-0.301-0.2206
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.324-2.79-0.465-0.58-0.384-0.056-0.046-0.05-0.069
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.260.260.0150000.25000.5
Period201720182019202020212022202320242025TTM
Sales, quarterly00000000.50
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual000.0010.0010.0190.1960.6181.199159.444174.443
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.1991.1994.3974.89.119159.444167.422173.595174.443
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.500.000.000.250.000.000.000.020.26
Cost of Goods Sold Incl. D&A-0.000.000.000.170.170.15--
Gross Profit--0.00-0.000.25-0.17-0.17-0.15--
Selling, General and Administrative Excl. Other48.6318.0514.8613.0915.1411.579.158.508.33
Research and Development30.5510.199.066.896.552.433.104.063.96
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-48.13-18.06-14.86-12.85-15.31-11.74-9.30-8.63-8.26
Interest Expense-0.010.010.010.012.400.230.010.01
Unusual Expense-0.03-0.350.000.17-0.9112.530.80-0.50-3.27
Net Income Before Taxes-43.70-16.78-14.44-12.30-14.26-26.62-10.32-8.35-4.92
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-43.70-16.78-14.44-12.32-14.55-26.62-10.32-8.35-4.92
Net Income From Continuing Operations-43.70-16.78-14.44-12.32-14.55-26.62-10.32-8.35-4.92
Net Income-43.70-16.78-14.44-12.32-14.55-26.62-10.32-8.35-4.92
EPS (Recurring)-0.21-0.31-10.19-26.75-258.70-1,842.56-15,830.46-17,818.38-42,830.05
EPS (Basic, Before Extraordinaries)-0.22-0.30-10.19-27.01-247.89-2,144.20-16,742.16-17,102.88-29,241.90
EPS (Diluted)-0.22-0.30-10.19-27.01-247.89-2,546.16-16,742.16-17,102.88-29,241.90
EBITDA-48.13-18.05-14.86-12.84-15.14-11.57-9.15-8.49-8.07
Non-Operating Income (Expense)4.410.930.430.730.160.050.01-0.210.07
Other After Tax Adjustments0.000.000.00-0.02-0.290.000.000.000.00
Stock Option Compensation Expense17.843.920.630.610.821.492.010.880.63
Price To Sales Ratio572.48--16.14--902.73141.3218.25
Gross Margin---98.40-----
Operating Margin-9,625.40---5,138.00----56,071.81-3,176.71
Net Margin-8,739.20---4,926.40----54,252.64-1,894.08
Shares Outstanding174.44159.441.200.620.200.020.000.000.00
Market Capitalization196.93196.934.565.438.0218.5115.223.835.70

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.500.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.00-0.000.000.000.000.000.00
Gross Profit0.00-0.000.00-0.00-0.00-0.000.00
Selling, General and Administrative Excl. Other15.7012.2010.759.982.922.842.313.38
Research and Development10.587.406.406.171.391.680.952.08
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-15.70-11.70-10.75-9.98-2.92-2.84-2.31-3.38
Interest Expense--0.000.000.010.000.000.00
Unusual Expense-0.010.01-0.01-0.03-0.330.010.00-0.16
Net Income Before Taxes-14.62-10.57-9.60-8.90-2.87-2.78-2.23-3.34
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-14.62-10.57-9.60-8.90-2.87-2.78-2.23-3.34
Net Income From Continuing Operations-14.62-10.57-9.60-8.90-2.87-2.78-2.23-3.34
Net Income-14.62-10.57-9.60-8.90-2.87-2.78-2.23-3.34
EPS (Recurring)-0.07-0.05-0.05-0.06-0.42-0.58-0.46-2.88
EPS (Basic, Before Extraordinaries)-0.07-0.05-0.05-0.06-0.38-0.58-0.47-2.79
EPS (Diluted)-0.07-0.05-0.05-0.06-0.38-0.58-0.47-2.79
EBITDA-15.70-11.70-10.75-9.98-2.92-2.84-2.31-3.38
Non-Operating Income (Expense)1.071.141.141.06-0.280.070.08-0.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.054.784.293.720.090.060.060.07
Price To Sales Ratio572.48883.58------
Operating Margin--2,339.60------
Net Margin--2,114.80------
Shares Outstanding174.44173.60167.42159.449.124.804.401.20
Market Capitalization196.93362.78290.30350.167.843.262.994.56

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments133.389.8212.4312.3810.490.715.115.7911.67
Short Term Receivables0.260.020.151.440.150.060.020.360.37
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.570.570.640.800.860.080.510.360.40
Total Current Assets134.2210.4213.2214.6211.510.855.656.5112.45
Net Property, Plant & Equipment0.000.090.210.310.110.280.240.090.17
Total Investments and Advances0.060.030.030.030.030.030.000.000.00
Long-Term Note Receivable------0.000.300.37
Intangible Assets-0.00--0.000.000.670.760.88
Other Assets0.070.350.600.810.871.860.030.020.01
Total Assets134.3410.8814.0515.7612.513.026.587.6813.88
Short Term Debt Incl. Current Port. of LT Debt0.070.170.280.190.201.220.030.000.00
Accounts Payable0.771.100.701.761.322.540.820.830.88
Other Current Liabilities3.801.961.611.060.974.330.370.220.64
Total Current Liabilities4.643.242.593.012.508.081.221.051.51
Long Term Debt0.000.000.090.210.000.210.150.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.330.150.060.062.651.830.080.583.85
Total Liabilities4.963.392.743.285.1510.121.461.635.37
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.009.500.000.010.01
Common Equity129.387.4911.3112.487.36-16.605.126.048.51
Total Shareholders Equity129.387.4911.3112.487.37-7.105.136.058.52
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity129.387.4911.3112.487.37-7.105.136.058.52
Total Liabilities & Stockholders Equity134.3410.8814.0515.7612.513.026.587.6813.88
Book Value Per Share0.816.2518.3063.57387.83-26,926.995,963.5929,857.6150,492.14
Tangible Book Value Per Share0.816.2518.3063.57387.83-26,926.995,185.0526,082.8945,247.32
Full-Time Employees148912137566
Price to Book Ratio1.610.300.390.652.511.560.750.942.25
Return on Assets-23.11-115.82-82.62-102.90-342.75-214.98-117.07-45.66-85.87
Return on Equity-24.52-153.55-103.53-146.62-20,012.03-218.44-149.46-67.62-157.88
Return on Invested Capital-12.97-192.71-108.01-114.64-361.38--158.34-81.40-183.98
Quick Ratio28.953.225.114.854.610.114.616.198.22
Current Ratio28.953.225.114.854.610.114.616.198.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-43.70-16.78-14.44-12.30-14.26-26.62-10.32-8.35-4.92
Depreciation0.000.000.000.000.170.170.150.140.19
Other Funds (Non Cash)17.794.290.850.76-0.5216.433.020.74-2.62
Funds from Operations-25.91-12.49-13.58-11.53-14.61-10.02-7.16-7.46-7.36
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.491.641.390.401.25-4.762.390.21-0.34
Cash from Operating Activities-26.40-10.85-12.19-11.13-13.36-14.77-4.77-7.26-7.69
Capital Expenditures0.000.000.00-0.00-0.010.00-0.010.00-0.00
Net Assets From Acquisitions0.000.000.000.000.00-0.050.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.005.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.005.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.00-0.01-0.05-0.010.005.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock135.07135.2510.3811.5816.0524.941.186.551.83
Repurchase of Common Pref Stock0.000.000.000.000.00-0.100.000.000.00
Sale of Common Pref Stock135.07135.2510.3811.5816.0525.041.186.551.83
Proceedsfrom Stock Options131.19127.627.878.8216.0525.041.180.000.00
Issuance or Reduction of Debt, Net-0.21-0.32-0.43-0.39-0.79-0.180.710.04-0.01
Change in Long Term Debt0.000.000.000.000.000.000.710.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.740.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.030.000.00
Net Financing Active Other Cash Flow-0.05-0.49-0.370.000.000.000.000.000.00
Other Financing Activities Uses-0.05-0.49-0.370.000.000.000.000.000.00
Cash from Financing Activities134.81134.449.5811.1915.2624.611.896.591.81
Exchange Rate Effect-------0.00-0.01-0.01
Net Change in Cash108.42123.59-2.610.051.899.78-2.88-0.67-0.89
Free Cash Flow-26.40-10.85-12.19-11.14-13.37-14.77-4.77-7.26-7.69
Preferred Dividends (Cash Flow)------0.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments113.61125.17132.63133.385.235.42
Short Term Receivables0.000.500.010.260.020.01
Inventories0.000.000.000.000.000.00
Other Current Assets3.791.510.610.570.960.74
Total Current Assets117.40127.19133.24134.226.216.16
Net Property, Plant & Equipment0.000.000.000.000.000.02
Total Investments and Advances0.060.060.060.060.030.03
Intangible Assets-0.00----
Other Assets1.090.070.020.070.740.46
Total Assets118.55127.31133.31134.346.976.67
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.070.210.34
Accounts Payable1.451.832.700.771.431.37
Other Current Liabilities4.383.412.923.801.842.26
Total Current Liabilities5.835.255.624.643.483.97
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.280.320.330.330.280.08
Total Liabilities6.115.575.954.963.764.05
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity112.44121.75127.36129.383.212.62
Total Shareholders Equity112.44121.75127.36129.383.212.62
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity112.44121.75127.36129.383.212.62
Total Liabilities & Stockholders Equity118.55127.31133.31134.346.976.67
Book Value Per Share0.640.700.760.810.350.55
Tangible Book Value Per Share0.640.700.760.810.350.55
Full-Time Employees---14--
Price to Book Ratio1.612.752.166.681.580.56
Return on Assets-69.63-47.68-34.13-23.11-137.67-121.25
Return on Equity-75.56-51.37-36.40-24.52-228.64-188.48
Return on Invested Capital-13.01-8.69-7.54-6.88-89.29-106.26
Quick Ratio20.1524.2523.7128.951.781.55
Current Ratio20.1524.2523.7128.951.781.55

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-14.62-10.57-9.60-8.90-2.87-2.78
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)5.074.774.303.640.380.17
Funds from Operations-9.55-5.80-5.30-5.26-2.48-2.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.21-1.801.412.11-1.070.80
Cash from Operating Activities-11.76-7.60-3.89-3.14-3.55-1.82
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock0.200.153.20131.523.910.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.200.153.20131.523.910.00
Proceedsfrom Stock Options0.203.24-0.05127.800.000.00
Issuance or Reduction of Debt, Net0.000.00-0.07-0.14-0.100.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.05-0.450.00
Other Financing Activities Uses0.000.000.00-0.05-0.450.00
Cash from Financing Activities0.200.153.13131.333.360.00
Net Change in Cash-11.56-7.46-0.76128.19-0.19-1.81
Free Cash Flow-11.76-7.60-3.89-3.14-3.55-1.82

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.22%29.3M160.7M2.74M
2026-10-1519.75%31.7M160.7M2.50M
2026-09-3018.87%31.0M164.3M2.78M
2026-09-1518.42%30.3M164.3M2.88M
2026-08-3118.81%30.9M164.3M2.95M
2026-08-1420.34%33.4M164.2M3.15M
2026-07-3120.19%33.7M166.9M3.34M
2026-07-1522.18%37.0M166.9M3.83M
2026-06-3019.20%32.1M167.4M4.00M
2026-06-1518.83%31.5M167.4M3.65M
2026-05-2918.02%30.8M171.0M3.72M
2026-05-1515.75%26.9M171.0M3.81M
2026-04-3016.03%26.1M163.1M3.93M
2026-04-1515.87%25.6M161.6M4.08M
2026-03-3116.14%25.8M159.7M4.43M
2026-03-1316.38%26.2M159.7M4.59M
2026-02-2718.64%26.7M143.4M5.04M
2026-02-1317.68%25.4M143.4M5.12M
2026-01-3014.16%21.1M149.0M5.20M
2026-01-1511.75%17.5M149.0M5.03M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-09SCHEDULE 13G/ASEC
2026-10-30SCHEDULE 13GSEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-213Initial statement of beneficial ownership of securities2026-10-19SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-29SCHEDULE 13GSEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-07144Filing for proposed sale of securities under Rule 144.SEC
2026-07-07144Filing for proposed sale of securities under Rule 144.SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-183Initial statement of beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-123Initial statement of beneficial ownership of securities2026-06-10SEC
2026-06-118-KCurrent report2026-06-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1028.80K200
2026-090000
2026-080000
2026-07250.18K6409.88K2
2026-060000
2026-050000
2026-040000
2026-030000
2026-020010.30K2
2026-0117.76K200
2025-120000
2025-110000

Institutional holders

Manager% owned
Soleus Capital Management, L.P.7.53%
B Group, Inc.6.58%
AMERIPRISE FINANCIAL INC6.38%
Jupiter Topco LLC6.16%
BlackRock, Inc.6.01%
Octagon Capital Advisors LP5.92%
PERCEPTIVE ADVISORS LLC4.85%
RA CAPITAL MANAGEMENT, L.P.4.10%
FRANKLIN RESOURCES INC3.33%
Point72 Asset Management, L.P.3.03%

Funds

Fund% owned
iShares Russell 2000 ETF2.15%
Federated Hermes Kaufmann Small Cap Fund1.81%
Franklin Biotechnology Discovery Fund1.22%
abrdn Life Sciences Investors1.10%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Fidelity Small Cap Index Fund0.93%
iShares Russell 2000 Value ETF0.64%
VANGUARD RUSSELL 2000 INDEX FUND0.48%
Nuveen Equity Index Fund0.45%
Fidelity Extended Market Index Fund0.42%

OakChart. PALI. Cached 15 minutes.